Renalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare Conference

Rhea-AI Summary

Renalytix plc (NASDAQ: RNLX) announces its participation in the 40th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 12, 2022, at 2:15 p.m. EST. Interested investors can access the live and archived webcast on the company’s investors page. Renalytix is pioneering bioprognosis for kidney health, with its flagship product, KidneyIntelX, receiving FDA Breakthrough Designation aimed at improving kidney disease management and patient care. For more details, visit www.renalytix.com.

NEW YORK and SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming 40^th Annual J.P. Morgan Virtual Healthcare Conference.

Renalytix’s management is scheduled to present on Wednesday, January 12, 2022, at 2:15 p.m. EST. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at investors.renalytix.com.

About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that successfully enables early-stage CKD progression risk assessment. The Company’s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth		Mob: 07980 541 893 / 07584 391 303
CapComm Partners
Peter DeNardo			Tel: 415-389-6400 or investors@renalytix.com

FAQ

When will Renalytix present at the J.P. Morgan Virtual Healthcare Conference?

Renalytix will present on January 12, 2022, at 2:15 p.m. EST.

How can I access Renalytix's conference presentation?

You can access the live and archived webcast on the 'Investors' section of Renalytix's website.

What is the main focus of Renalytix's business?

Renalytix focuses on bioprognosis for kidney health, specifically through their product, KidneyIntelX.

What is KidneyIntelX and its significance?

KidneyIntelX is a product by Renalytix designed to improve kidney disease prognosis and has received FDA Breakthrough Designation.

What ticker symbol is Renalytix listed under?

Renalytix is listed under the ticker symbol RNLX on NASDAQ.